Canada: Canada Closes Door To Consumer Class Actions Based On Invalidated Pharma Patents

Following a landmark decision from the Supreme Court of Canada in 2012, the Federal Court of Appeal invalidated the Pfizer patent to the active ingredient in Viagra.1 Subsequently, a class action was initiated in the Supreme Court of British Columbia alleging that Pfizer had injured consumers who had purchased Viagra at inflated prices, because the invalid patent had kept generic competitors off the market.

The parties agreed to bifurcate the certification process, with the result that the Supreme Court of British Columbia was asked initially to determine whether the cause of action requirement for certification was met. The Court held in first instance that the claim disclosed a cause of action. Pfizer appealed the decision.

What You Need To Know

  • The Court of Appeal for British Columbia has ruled that the claim did not disclose a cause of action, and hence that this requirement for certification was not met because:2

    • the Patent Act is a complete code which precludes any civil claims by consumers rooted in a breach of the statute.
    • A breach of the Patent Act by Pfizer cannot constitute the "unlawful act" on which a claim for unlawful interference with economic relations can be based.
    • The plaintiff could not seek recovery based on principles of unjust enrichment since there was a juristic reason for Pfizer's alleged enrichment (namely, the contracts of purchase and sale between Pfizer and direct purchasers of Viagra).
  • There are at least three additional class actions in Canada with similar causes of action in early stages. None have been certified. If the Court of Appeal's ruling stands, these actions may not proceed any further.

Novel Targeting of Innovative Drug Manufacturers

Recent claims, including class actions brought by consumers, have targeted the profits earned by innovative drug manufacturers on the basis of allegations that the innovator has availed itself of its rights under the Patent Act and PM(NOC) Regulations in such a way as to wrongfully extend the period of patent protection and market exclusivity.

One proposed consumer class action, Low v Pfizer Canada Inc., had initially been partially certified by the Supreme Court of British Columbia, which held that the claim disclosed valid causes of action for intentional interference with economic relations, or unjust enrichment.3 Similar class actions have been filed in Manitoba and Saskatchewan.4 5

These class actions stem from a 2012 decision of the Supreme Court of Canada rendered in the context of Canada's PM(NOC) Regulations,6 as well as a subsequent 2012 Federal Court of Appeal decision. The combined effect of these decisions was to invalidate a key Pfizer patent to sildenafil, the active ingredient in Viagra. The main thrust of the plaintiff's claim in Low was that Pfizer had manipulated the Canadian patent system in order to wrongfully extend Viagra's patent protection, and hence its market exclusivity in Canada.

The Supreme Court of British Columbia held in first instance that the claim disclosed a cause of action, and therefore met the requirements of the Class Proceedings Act in this regard.

The Court of Appeal has overturned this decision, and has ruled that the Patent Act and PM(NOC) Regulations form a complete code which precludes the possibility of a parallel civil claim by a consumer. The Court held that it would not make sense to allow consumers to claim disgorgement of profits earned by the innovative brand manufacturer when generic manufacturers have no such recourse.

The Court of Appeal also held that the plaintiff was improperly seeking to use the common law to expand the scope of the Patent Act, and that such an expansion was impermissible under Canadian law, which does not allow an independent cause of action for "breach of statute."

Further, the Court of Appeal held that the alleged breach of the Patent Act by Pfizer could not ground a claim for unlawful interference with economic relations, because that alleged breach is not an "actionable civil wrong," since a generic manufacturer cannot claim unjust enrichment or disgorgement of profits. Rather, under the PM(NOC) Regulations, the generic manufacturer's claim is limited to its own losses. Therefore, an innovative manufacturer could not face greater liability to a consumer than to a generic manufacturer for the same conduct, namely an alleged breach of the Patent Act.

With respect to the claim for unjust enrichment, the Supreme Court of British Columbia noted that Pfizer had entered into contracts of purchase and sale with direct purchasers of Viagra, such as distributors and pharmacies. Those contracts provided a "juristic reason" for Pfizer's enrichment from sales of Viagra. Accordingly, the Court of Appeal found that there was no valid claim to unjust enrichment, as the existence of any "juristic reason" for enrichment precludes a claim for unjust enrichment.

The Court of Appeal's ruling, if it stands, would appear to foreclose the possibility of innovative drug manufacturers facing enhanced liability if their patents are ultimately found to be invalid. While innovators remain liable to generic drug manufacturers under the PM(NOC) Regulations, those Regulations, together with the Patent Act, form a "complete code" which precludes the possibility of parallel civil actions by consumers.

Either party may seek leave to appeal from the Supreme Court of Canada until February 8, 2016.


1. Apotex Inc. v Pfizer Ireland Pharmaceuticals, 2012 FC 1339, aff'd 2014 FCA 13.

2. Low v Pfizer Canada Inc., 2015 BCCA 506.

3. Low v Pfizer Canada Inc, 2014 BCSC 1469.

4. Thompson v Pfizer Canada Inc., Court file no. CJ14-01-88141; Andres v Pfizer Canada Inc., Court file no. QBG 122 of 2014.

5. An additional B.C. class action against Pfizer was also commenced but did not proceed: Sewell v Pfizer Canada Inc., Court file no. VLC-S-S-128762.

6. The PM(NOC) Regulations allow innovative drug manufacturers to seek to prohibit a prohibition order preventing a generic drug product from being approved until the patents for the drug product listed on "Canada's Orange Book" have expired. Under the Regulations, if a generic drug manufacturer is improperly delayed in getting its drug product approved, the generic manufacturer may claim against the innovative manufacturer for damages, but not disgorgement of profits, resulting from the delay. However, there is nothing in the legislation that allows consumers or patients to make any claims in such a scenario. This regime is similar to the U.S. system under the Hatch-Waxman Act.

Originally published December 15, 2015

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions